-
Tenofovir disoproxil, sold
under the
brand name
Viread among others, is a
medication used to
treat chronic hepatitis B and to
prevent and
treat HIV/AIDS...
- PMC 6124415. PMID 30046000.
Viread Label Information, U.S. Food and Drug
Administration (FDA), 2008-04-11
Tenofovir (
Viread) ****ociated with Mild Kidney...
-
Gilead Sciences,
received approval for the oral
powder formulation of
Viread (tenofovir disoproxil). On
September 3, 2013, the
company launched PYLERA...
- is also
marketed in a fixed-dose
combination with
tenofovir disoproxil (
Viread)
under the
brand name Truvada, and with
tenofovir alafenamide (Vemlidy)...
- that decade. In the 2000s,
Gilead received approval for
drugs including Viread and Hepsera,
among others. It
began evolving from a
biotechnology company...
-
expiration of the US
patents on
dolutegravir (Tivicay) and
tenofovir disoproxil (
Viread). As of 2019, it is
listed by the
World Health Organization (WHO) as the...
- a student, Cihlář ****isted
fellow biochemist Antonín Holý in
developing Viread, the
primary drug used to
fight HIV infection. Cihlář
graduated from the...
-
analogues zidovudine (trade name Retrovir),
lamivudine (Epivir) and
tenofovir (
Viread), as well as non-nucleoside inhibitors, such as
nevirapine (Viramune).[citation...
- 2012). "GS-7340
Packs Greater HIV Punch,
Potentially Better Safety,
Versus Viread". AIDSmeds.com.
Archived from the
original on 8
September 2015. "Pharmacokinetics...
-
December 2020. "GlaxoSmithKline and
Gilead announce agreement to
commercialise Viread® for
chronic hepatitis B in key
Asian countries". GlaxoSmithKline. 23 November...
